While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies.
The Healthy Mother - Healthy Baby intervention delivered by non-specialists cuts postpartum depression risk by 81% through anxiety-focused care.
Blood levels of neuroactive steroids during the third trimester of pregnancy may predict increased risk of postpartum depression, offering possibility for early intervention.
According to a recent meta-analysis, about one out of every five women has at least one type of anxiety disorder during pregnancy or the postpartum period.
Several studies suggest that screening during the first week postpartum may be helpful in identifying women at higher risk for experiencing postpartum depression.
While we have adequate data to support the use of SSRI and SNRI antidepressants during pregnancy, there is less data regarding other classes of antidepressants. Although we less commonly use mirtazapine in pregnancy, several [...]
The MGHP3 study provides key insights into the onset, duration, treatment, and characteristics of postpartum psychosis in a large, diverse cohort.
Based on the findings of two meta-analyses and several large cohort studies, we cannot conclude that cannabis is “safe” for use during pregnancy. Data regarding risk for autism spectrum disorder is mixed.
Because women with bipolar disorder are at high risk for relapse during the postpartum period, we typically recommend that women continue treatment with lithium throughout the postpartum period. While this intervention clearly decreases risk for postpartum psychiatric illness, the use of lithium while breastfeeding presents certain challenges.
Xylazine, a veterinary sedative, has become an increasingly common adulterant in the illicit opioid supply, posing unique risks to pregnant individuals and their developing fetuses.
